JCB logo
Keystone Symposia 2009 Meetings
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published 24 April 2006. doi:10.1083/jcb.200506033
The Rockefeller University Press, 0021-9525 $8.00
JCB, Volume 173, Number 2, 301-310
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 2717K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sukocheva, O.
Right arrow Articles by Xia, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sukocheva, O.
Right arrow Articles by Xia, P.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Article

 Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1

Olga Sukocheva1, Carol Wadham1, Andrew Holmes1, Nathaniel Albanese1, Emily Verrier1, Feng Feng1, Alex Bernal3, Claudia K. Derian3, Axel Ullrich4, Mathew A. Vadas1,2, and Pu Xia1,2

1 Signal Transduction Laboratory, Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide SA 5000, Australia
2 Department of Medicine, Adelaide University, Adelaide SA 5000, Australia
3 Johnson & Johnson Pharmaceutical Research and Development, Spring House, PA, 19477
4 Department of Molecular Biology, Max Planck Institute for Biochemistry, 80539 Munich, Germany

Correspondence to Pu Xia: pu.xia{at}imvs.sa.gov.au

The transactivation of enhanced growth factor receptor (EGFR) by G protein–coupled receptor (GPCR) ligands is recognized as an important signaling mechanism in the regulation of complex biological processes, such as cancer development. Estrogen (E2), which is a steroid hormone that is intimately implicated in breast cancer, has also been suggested to function via EGFR transactivation. In this study, we demonstrate that E2-induced EGFR transactivation in human breast cancer cells is driven via a novel signaling system controlled by the lipid kinase sphingosine kinase-1 (SphK1). We show that E2 stimulates SphK1 activation and the release of sphingosine 1-phosphate (S1P), by which E2 is capable of activating the S1P receptor Edg-3, resulting in the EGFR transactivation in a matrix metalloprotease–dependent manner. Thus, these findings reveal a key role for SphK1 in the coupling of the signals between three membrane-spanning events induced by E2, S1P, and EGF. They also suggest a new signal transduction model across three individual ligand-receptor systems, i.e., "criss-cross" transactivation.

Abbreviations used in this paper: AO, antisense oligonucleotide; CM, conditioned media; EGFR, EGF receptor; ER, estrogen receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GPCR, G protein–coupled receptor; HB-EGF, heparin-binding EGF; mER, membrane-associated ER; MMP, matrix metalloprotease; p-EGFR, phosphorylated EGFR; p-ERK1/2, phosphorylated ERK1/2; PTX, pertussis toxin; S1P, sphingosine 1-phosphate; SphK, sphingosine kinase.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents